GlassScriptPhysician profile
Richard Sue
NPI 1053320168
$224,372.78
in general payments reported to CMS, 2019-2025
20 companies · $401 in 2025
The $401 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $81K · 2021: $26K · 2022: $55K · 2023: $12K · 2024: $1,091 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,300 · Travel and Lodging: $3,102 · Food and Beverage: $1,270 · Education: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,300.00 |
| Travel and Lodging | $3,102.21 |
| Food and Beverage | $1,270.02 |
| Education | $318.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $218,123.54 | 2019-2025 | Zephyr Delivery Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Intuitive Surgical, INC. | $1,932.85 | 2022-2025 | Da Vinci Surgical System |
| Csa Medical, INC | $1,281.64 | 2019 | |
| Genentech, INC. | $930.00 | 2021 | |
| Ethicon INC. | $905.26 | 2019-2025 | Monarch Platform |
| Boston Scientific Corporation | $319.45 | 2020-2023 | Exalt Model D |
| Galvanize Therapeutics, INC | $194.76 | 2022 | |
| Noah Medical Corporation | $138.94 | 2024 | Galaxy |
| Veran Medical Technologies, INC. | $135.89 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $94.76 | 2019 | |
| Olympus America INC. | $78.67 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $63.41 | 2022-2023 | Uptravi |
| La Jolla Pharmaceutical Company | $46.40 | 2024 | Giapreza |
| Glaxosmithkline, LLC. | $36.74 | 2019-2025 | Trelegy Ellipta |
| Vapotherm INC | $28.47 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $23.21 | 2019 | |
| Imbio INC. | $15.96 | 2023 | Imbio Lung Density Analysis |
| Janssen Biotech, INC. | $11.88 | 2022 | |
| Electromed, INC. | $10.95 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Sue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.